Population-Wide Screening for Chronic Kidney Disease

LettersJanuary 2024Population-Wide Screening for Chronic Kidney DiseaseDominique van Mil, MD, Hiddo L. Heerspink, PhD, Ron T. Gansevoort, MD, PhDDominique van Mil, MDUniversity Medical Center Groningen, Groningen, The NetherlandsSearch for more papers by this author, Hiddo L. Heerspink, PhDUniversity Medical Center Groningen, Groningen, The NetherlandsSearch for more papers by this author, Ron T. Gansevoort, MD, PhDUniversity Medical Center Groningen, Groningen, The NetherlandsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L23-0369 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Cusick and colleagues' model (1) showed that screening the general population for albuminuria with subsequent treatment of those identified as having chronic kidney disease could be cost-effective in the United States. The incremental cost-effectiveness ratio was $86 300 per quality-adjusted life-year (QALY). This may be acceptable for the United States, where commonly applied willingness-to-pay thresholds are $100 000 and $150 000 per QALY; for many other countries, the willingness-to-pay threshold is unfortunately lower. However, the cost-effectiveness of general population screening for albuminuria may be more beneficial.First, Cusick and colleagues modeled albuminuria screening performed by a primary care provider at ...References1. Cusick MM, Tisdale RL, Chertow GM, et al. Population-wide screening for chronic kidney disease. A cost-effectiveness analysis. Ann Intern Med. 2023;176:788-797. [PMID: 37216661] doi:10.7326/M22-3228 LinkGoogle Scholar2. van Mil D, Kieneker LM, Evers-Roeten B, et al. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. Lancet. 2023;402:1052-1064. [PMID: 37597522] doi:10.1016/S0140-6736(23)00876-0 CrossrefMedlineGoogle Scholar3. Physicians' Academy for Cardiovascular Education. Comparing two screening methods for albuminuria in the general population. 23 May 2022. Accessed at https://pace-cme.org/2022/05/23/comparing-two-screening-methods-for-albuminuria-in-the-general-population on 4 June 2023. Google Scholar4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339-52. [PMID: 23727170] doi:10.1016/S0140-6736(13)60595-4 CrossrefMedlineGoogle Scholar5. Kearney J, Gnudi L. The pillars for renal disease treatment in patients with type 2 diabetes. Pharmaceutics. 2023;15. [PMID: 37242585] doi:10.3390/pharmaceutics15051343 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Dominique van Mil, MD; Hiddo L. Heerspink, PhD; Ron T. Gansevoort, MD, PhDAffiliations: University Medical Center Groningen, Groningen, The NetherlandsDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L23-0369. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPopulation-Wide Screening for Chronic Kidney Disease Marika M. Cusick , Rebecca L. Tisdale , Glenn M. Chertow , Douglas K. Owens , and Jeremy D. Goldhaber-Fiebert Population-Wide Screening for Chronic Kidney Disease Marika M. Cusick , Rebecca L. Tisdale , Glenn M. Chertow , Douglas K. Owens , Jeremy D. Goldhaber-Fiebert Metrics Current Issue January 2024Volume 177, Issue 1 Keywords ACE inhibitor therapy Age groups Angiotensin converting enzyme Estimated glomerular filtration rate Health screening Mortality Quality adjusted life years Quality of life ePublished: 16 January 2024 Issue Published: January 2024 Copyright & PermissionsCopyright © 2024 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...